A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Recruiting now · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer (NSCLC)

In brief

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.

Key facts

Study ID
NCT06754930
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
People needed
400
Starts
2025-02-18
Expected to finish
2027-12-01
Last updated by the study team
2025-04-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.